Skip to main content

Nilanjana Banerji

  • Nilanjana Banerji, PhD, director, clinical research, Courage Kenny Research Center

    Nilanjana BanerjiNilanjana Banerji, PhD, is director of clinical research for Courage Kenny Rehabilitation Center and John Nasseff Neuroscience Institute. Her goal is to utilize her experience in research operations to further Courage Kenny Rehabilitation Institute’s research program in a team-oriented, cross-cultural environment.  Her ultimate goal is to lead and catalyze Courage Kenny into a leading research institute in the field that helps the people it serves achieve health and wellness by offering excellent services, innovative programs, and ground-breaking research to maximize the quality of life and health.

    Dr. Banerji joined Allina Health in 2007 and has, since then, administered research operations in the areas of oncology, neuroscience, and rehabilitation. Most recently, in her leadership role with Allina Health’s John Nasseff Neuroscience Institute, Dr. Banerji supervised the operational development of the Research Department and established a robust research agenda in neuroscience. Her responsibilities included strategic planning and development of research activities, assisting with research infrastructure advancement, and development of new research and research-related initiatives.

    Dr. Banerji is a member of the Allina Health Institutional Review Board (IRB). She has worked in collaboration with the IRB and Office of Sponsored Project Administration to oversee and guide the regulatory research functions to ensure that the Allina Health is compliant with federal and local standards in its research activities. Her research work has been published in numerous journals including Oncotarget, PNAS, Surgical Endoscopy, and Diseases of the Esophagus and she has co-authored a book chapter. She holds a master’s degree in biochemistry with specialization in molecular biology and a doctoral degree in biochemistry. Her post-doctoral training and academic work at the University of Minnesota focused on genetic profiling of pathways related to pathogenesis and progression of soft tissue sarcomas and basal cell carcinomas.